

HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the
Ending the HIV Epidemic Initiative:
(*preliminary data*):**

**National HIV Surveillance System Data
Reported Through March 2025**



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for persons with diagnosed HIV reported to CDC through March 2025.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2025. *HIV Surveillance Data Tables* 2025;6(1). <https://www.cdc.gov/hiv-data/initiatives/>. Published September 2025. Accessed [date].

On the Web: <https://www.cdc.gov/hiv-data/initiatives/>

Confidential information, referrals, and educational material on HIV

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

This issue of *HIV Surveillance Data Tables* was prepared by the HIV Surveillance Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	6
Tables	
1a HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through March 2025—United States (preliminary)	7
1b HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through March 2025—United States and 6 territories and freely associated states (preliminary)	8
1c HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through March 2025—United States and 6 territories and freely associated states (preliminary)	9
1d HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through March 2025—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, 2024—United States (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, 2024—United States and Puerto Rico (preliminary)	13
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	14
3 Ending the HIV Epidemic Phase I jurisdictions	16

Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core indicators for monitoring the Ending the HIV Epidemic initiative* report, available at <https://stacks.cdc.gov/view/cdc/156512>.

The tables included in this report provide *preliminary* data on HIV diagnoses for the years 2024 and 2025 and linkage to HIV medical care for the year 2024 based on cases reported to CDC as of March 2025. Data for the 2 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. More information on HIV surveillance practices and limitations, demographic information, and geographic designations can be found in the Technical Notes for the National HIV Surveillance System (NHSS), available at <https://www.cdc.gov/hiv-data/nhss/>.

TABULATION AND PRESENTATION OF DATA

HIV Diagnoses

HIV diagnoses are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2024 through March 2025 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2019–2023 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the years 2024 and 2025 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting HIV diagnoses can be found in the *HIV Surveillance Report, 2023*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-and-prevalence-2025.html>.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years with HIV diagnosed during the year 2024 (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years with HIV diagnosed during the year 2024 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed during the year 2024. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during the year 2024 and reported to NHSS through March 2025. Data for the year 2024 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

National analyses include data from the United States, including all 50 states and the District of Columbia. While data for Idaho were included in national and regional analyses, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2023*, available at <https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html>.

References

1. HHS. EHE Overview. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated March 2025. Accessed August 8, 2025.

Table 1a. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through March 2025—United States (*preliminary*)

	No.	No.
	2024	2025 (January–March)
Sex		
Male	30,321	4,618
Female	7,785	1,159
Age at diagnosis (yr)		
13–24	6,723	940
25–34	13,889	2,099
35–44	9,006	1,393
45–54	4,667	707
55–64	2,790	500
≥65	1,031	138
Race/ethnicity		
American Indian/Alaska Native	190	38
Asian	778	113
Black/African American	14,837	2,430
Hispanic/Latino ^a	13,226	1,726
Native Hawaiian/other Pacific Islander	90	10
White	8,081	1,383
Multiracial	904	77
Transmission category^b		
Male-to-male sexual contact ^c	24,890	3,810
Injection drug use ^d		
Male	1,326	202
Female	1,061	148
Male-to-male sexual contact ^c and injection drug use ^d	1,189	168
Heterosexual contact ^e		
Male	2,878	432
Female	6,674	1,002
Other ^f		
Male	38	6
Female	50	9
Region of residence^g		
Northeast	5,322	694
Midwest	5,271	777
South	20,025	3,282
West	7,488	1,024
Total	38,106	5,777

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through March 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

Table 1b. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through March 2025—United States and 6 territories and freely associated states (preliminary)

	No. 2024	No. 2025 (January–March)
Sex		
Male	30,612	4,648
Female	7,843	1,162
Age at diagnosis (yr)		
13–24	6,767	945
25–34	14,013	2,111
35–44	9,087	1,398
45–54	4,719	712
55–64	2,817	504
≥ 65	1,052	140
Race/ethnicity		
American Indian/Alaska Native	190	38
Asian	779	113
Black/African American	14,846	2,430
Hispanic/Latino ^a	13,556	1,759
Native Hawaiian/other Pacific Islander	94	10
White	8,086	1,383
Multiracial	904	77
Transmission category^b		
Male-to-male sexual contact ^c	25,107	3,830
Injection drug use ^d		
Male	1,341	202
Female	1,064	148
Male-to-male sexual contact ^c and injection drug use ^d	1,198	168
Heterosexual contact ^e		
Male	2,928	442
Female	6,728	1,005
Other ^f		
Male	38	6
Female	51	9
Region of residence^g		
Northeast	5,322	694
Midwest	5,271	777
South	20,025	3,282
West	7,488	1,024
U.S. territories and freely associated states	349	33
Total	38,455	5,810

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through March 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau.

^a Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

^g Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

Table 1c. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through March 2025—United States and 6 territories and freely associated states (preliminary)

Area of residence	No.	No.
	2024	2025 (January–March)
Alabama	556	87
Alaska	28	6
Arizona	899	115
Arkansas	328	84
California	4,313	530
Colorado	469	90
Connecticut	259	28
Delaware	119	16
District of Columbia	192	21
Florida	4,478	878
Georgia	2,554	467
Hawaii	69	3
Idaho	41	0
Illinois	1,402	112
Indiana	632	97
Iowa	116	32
Kansas	146	20
Kentucky	361	40
Louisiana	920	226
Maine	68	16
Maryland	776	89
Massachusetts	506	21
Michigan	689	153
Minnesota	311	58
Mississippi	483	86
Missouri	568	69
Montana	28	3
Nebraska	136	4
Nevada	600	46
New Hampshire	31	5
New Jersey	909	108
New Mexico	141	50
New York	2,503	322
North Carolina	1,369	253
North Dakota	20	4
Ohio	942	158
Oklahoma	319	60
Oregon	211	40
Pennsylvania	939	185
Rhode Island	93	6
South Carolina	767	132
South Dakota	35	5
Tennessee	880	146
Texas	4,972	549
Utah	201	26
Vermont	14	3
Virginia	861	132
Washington	473	114
West Virginia	90	16
Wisconsin	274	65
Wyoming	15	1
Subtotal	38,106	5,777
U.S. territories and freely associated states		
American Samoa	1	0
Guam	4	0
Northern Mariana Islands	0	0
Puerto Rico	330	33
Republic of Palau	0	0
U.S. Virgin Islands	14	0
Subtotal	349	33
Total	38,455	5,810

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at HIV diagnosis. Numbers less than 12 should be interpreted with caution. Data are for cases reported to CDC through March 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through March 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	No.	No.
	2024	2025 (January–March)
Arizona		
Maricopa County	613	85
California		
Alameda County	183	20
Los Angeles County	1,396	159
Orange County	220	43
Riverside County	281	29
Sacramento County	154	4
San Bernardino County	247	11
San Diego County	392	45
San Francisco County	184	34
District of Columbia	192	21
Florida		
Broward County	576	108
Duval County	259	52
Hillsborough County	290	55
Miami-Dade County	1,070	194
Orange County	431	104
Palm Beach County	338	68
Pinellas County	162	35
Georgia		
Cobb County	150	28
DeKalb County	315	65
Fulton County	486	108
Gwinnett County	235	35
Illinois		
Cook County	980	53
Indiana		
Marion County	286	42
Louisiana		
East Baton Rouge Parish	121	21
Orleans Parish	149	42
Maryland		
Baltimore City	177	23
Montgomery County	113	11
Prince George's County	233	21
Massachusetts		
Suffolk County	121	11
Michigan		
Wayne County	293	63
Nevada		
Clark County	547	37
New Jersey		
Essex County	195	26
Hudson County	110	12

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through March 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	No.	No.
	2024 (<i>cont</i>)	2025 (January–March) (<i>cont</i>)
New York		
Bronx County	406	50
Kings County	541	56
New York County	339	50
Queens County	426	58
North Carolina		
Mecklenburg County	277	57
Ohio		
Cuyahoga County	156	28
Franklin County	185	44
Hamilton County	122	17
Pennsylvania		
Philadelphia County	382	67
Puerto Rico		
San Juan Municipio	90	8
Tennessee		
Shelby County	319	57
Texas		
Bexar County	373	55
Dallas County	901	95
Harris County	1,266	141
Tarrant County	387	39
Travis County	238	41
Washington		
King County	200	59
Total	18,107	2,587

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through March 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, 2024—United States (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Sex					
Male	30,321	25,432	83.9	4,889	16.1
Female	7,785	6,390	82.1	1,395	17.9
Age at diagnosis (yr)					
13–24	6,723	5,519	82.1	1,204	17.9
25–34	13,889	11,681	84.1	2,208	15.9
35–44	9,006	7,542	83.7	1,464	16.3
45–54	4,667	3,862	82.8	805	17.2
55–64	2,790	2,361	84.6	429	15.4
≥65	1,031	857	83.1	174	16.9
Race/ethnicity					
American Indian/Alaska Native	190	162	85.3	28	14.7
Asian	778	673	86.5	105	13.5
Black/African American	14,837	12,014	81.0	2,823	19.0
Hispanic/Latino ^a	13,226	11,407	86.2	1,819	13.8
Native Hawaiian/other Pacific Islander	90	71	78.9	19	21.1
White	8,081	6,728	83.3	1,353	16.7
Multiracial	904	767	84.8	137	15.2
Transmission category^b					
Male-to-male sexual contact ^c	24,890	20,979	84.3	3,911	15.7
Injection drug use ^d	2,387	1,953	81.8	434	18.2
Male	1,326	1,092	82.4	234	17.6
Female	1,061	861	81.1	200	18.9
Male-to-male sexual contact ^c and injection drug use ^d	1,189	975	82.0	214	18.0
Heterosexual contact ^e	9,552	7,843	82.1	1,709	17.9
Male	2,878	2,356	81.9	522	18.1
Female	6,674	5,487	82.2	1,188	17.8
Region of residence^f					
Northeast	5,322	4,648	87.3	674	12.7
Midwest	5,271	4,484	85.1	787	14.9
South	20,025	16,363	81.7	3,662	18.3
West	7,488	6,327	84.5	1,161	15.5
Total^g	38,106	31,822	83.5	6,284	16.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are for cases reported to CDC through March 2025, are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Small numbers, and percentages based on these numbers, should be interpreted with caution. Data are based on residence at the time of HIV diagnosis. National analyses include data from the United States, including all 50 states and the District of Columbia. Data for Idaho were included in national and regional analyses; however, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

^a Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of data presented by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^g Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, 2024—United States and Puerto Rico (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Alabama	556	425	76.4	131	23.6
Alaska	28	23	82.1	5	17.9
Arizona	899	754	83.9	145	16.1
Arkansas	328	267	81.4	61	18.6
California	4,313	3,656	84.8	657	15.2
Colorado	469	357	76.1	112	23.9
Connecticut	259	229	88.4	30	11.6
Delaware	119	100	84.0	19	16.0
District of Columbia	192	159	82.8	33	17.2
Florida	4,478	3,684	82.3	794	17.7
Georgia	2,554	2,018	79.0	536	21.0
Hawaii	69	55	79.7	14	20.3
Illinois	1,402	1,219	86.9	183	13.1
Indiana	632	510	80.7	122	19.3
Iowa	116	103	88.8	13	11.2
Kansas	146	120	82.2	26	17.8
Kentucky	361	288	79.8	73	20.2
Louisiana	920	756	82.2	164	17.8
Maine	68	56	82.4	12	17.6
Maryland	776	687	88.5	89	11.5
Massachusetts	506	454	89.7	52	10.3
Michigan	689	579	84.0	110	16.0
Minnesota	311	278	89.4	33	10.6
Mississippi	483	348	72.0	135	28.0
Missouri	568	459	80.8	109	19.2
Montana	28	27	96.4	1	3.6
Nebraska	136	107	78.7	29	21.3
Nevada	600	547	91.2	53	8.8
New Hampshire	31	22	71.0	9	29.0
New Jersey	909	756	83.2	153	16.8
New Mexico	141	115	81.6	26	18.4
New York	2,503	2,207	88.2	296	11.8
North Carolina	1,369	1,119	81.7	250	18.3
North Dakota	20	20	100	0	0.0
Ohio	942	817	86.7	125	13.3
Oklahoma	319	255	79.9	64	20.1
Oregon	211	185	87.7	26	12.3
Pennsylvania	939	824	87.8	115	12.2
Puerto Rico	330	248	75.2	82	24.8
Rhode Island	93	86	92.5	7	7.5
South Carolina	767	683	89.0	84	11.0
South Dakota	35	30	85.7	5	14.3
Tennessee	880	656	74.5	224	25.5
Texas	4,972	4,108	82.6	864	17.4
Utah	201	142	70.6	59	29.4
Vermont	14	14	100	0	0.0
Virginia	861	737	85.6	124	14.4
Washington	473	417	88.2	56	11.8
West Virginia	90	73	81.1	17	18.9
Wisconsin	274	242	88.3	32	11.7
Wyoming	15	13	86.7	2	13.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are for cases reported to CDC through March 2025, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Small numbers, and percentages based on these numbers, should be interpreted with caution. Data are based on residence at time of HIV diagnosis. National analyses include data from the United States, including all 50 states and the District of Columbia. Data for Idaho were included in national and regional analyses; however, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Arizona					
Maricopa County	613	518	84.5	95	15.5
California					
Alameda County	183	170	92.9	13	7.1
Los Angeles County	1,396	1,171	83.9	225	16.1
Orange County	220	200	90.9	20	9.1
Riverside County	281	220	78.3	61	21.7
Sacramento County	154	126	81.8	28	18.2
San Bernardino County	247	184	74.5	63	25.5
San Diego County	392	345	88.0	47	12.0
San Francisco County	184	175	95.1	9	4.9
District of Columbia	192	159	82.8	33	17.2
Florida					
Broward County	576	470	81.6	106	18.4
Duval County	259	204	78.8	55	21.2
Hillsborough County	290	237	81.7	53	18.3
Miami-Dade County	1,070	848	79.3	222	20.7
Orange County	431	364	84.5	67	15.5
Palm Beach County	338	286	84.6	52	15.4
Pinellas County	162	129	79.6	33	20.4
Georgia					
Cobb County	150	130	86.7	20	13.3
DeKalb County	315	268	85.1	47	14.9
Fulton County	486	393	80.9	93	19.1
Gwinnett County	235	201	85.5	34	14.5
Illinois					
Cook County	980	862	88.0	118	12.0
Indiana					
Marion County	286	238	83.2	48	16.8
Louisiana					
East Baton Rouge Parish	121	99	81.8	22	18.2
Orleans Parish	149	123	82.6	26	17.4
Maryland					
Baltimore City	177	160	90.4	17	9.6
Montgomery County	113	99	87.6	14	12.4
Prince George's County	233	206	88.4	27	11.6
Massachusetts					
Suffolk County	121	114	94.2	7	5.8
Michigan					
Wayne County	293	241	82.3	52	17.7
Nevada					
Clark County	547	499	91.2	48	8.8
New Jersey					
Essex County	195	154	79.0	41	21.0
Hudson County	110	89	80.9	21	19.1
New York					
Bronx County	406	352	86.7	54	13.3
Kings County	541	454	83.9	87	16.1
New York County	339	303	89.4	36	10.6
Queens County	426	378	88.7	48	11.3

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
North Carolina					
Mecklenburg County	277	240	86.6	37	13.4
Ohio					
Cuyahoga County	156	140	89.7	16	10.3
Franklin County	185	166	89.7	19	10.3
Hamilton County	122	101	82.8	21	17.2
Pennsylvania					
Philadelphia County	382	325	85.1	57	14.9
Puerto Rico					
San Juan Municipio	90	65	72.2	25	27.8
Tennessee					
Shelby County	319	215	67.4	104	32.6
Texas					
Bexar County	373	302	81.0	71	19.0
Dallas County	901	753	83.6	148	16.4
Harris County	1,266	1,034	81.7	232	18.3
Tarrant County	387	327	84.5	60	15.5
Travis County	238	216	90.8	22	9.2
Washington					
King County	200	178	89.0	22	11.0
Total	18,107	15,231	84.1	2,876	15.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care are for persons with HIV diagnosed during January 2024 through March 2025 and reported to NHSS through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Small numbers, and percentages based on these numbers, should be interpreted with caution. Data are based on residence at time of HIV diagnosis.

Table 3. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico	Alabama
Maricopa County	San Juan Municipio	Arkansas
California		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey		
Essex County		
Hudson County		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 3. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.